It is no secret that compliance programs in many med-tech companies lag behind current compliance best practices. There are many possible reasons for this: Life Science compliance is dominated by pharmaceutical settlements. The pharmaceutical regulatory scheme is more established (1938 vs. 1976). Medical technology companies have fewer resources overall. Regardless of the reason, 2 recent cases (Olympus and Invacare) and a McKinsey study clearly demonstrate that med-tech companies can no longer…
The post Med-Tech Compliance Comes of Age appeared first on Whitelaw Compliance Group, LLC.